Invivoscribe will develop and commercialize molecular diagnostics that run on Thermo's Ion PGM Dx system, as well as associated bioinformatic software.
The diagnostics firm recorded $3.2 million in revenues for the quarter and $8.4 million for the year, beating analysts' estimates.
The company estimates Humana owes it upwards of $800,000 in payment for nearly 4,700 Cologuard tests it has performed since October 2014.
The company, based in Constance, Germany, is launching three liquid biopsy assays as a research service this week that differ in target size and sensitivity.
Icon will use its data management capabilities and clinical trials expertise to validate clinical data from the 70,000 participating patients and their families.
In Cell this week: characterization of functional genomic features in breast cancer cell lines, epigenetic pattern linked to obesity, and more.
President Obama's proposed budget for fiscal year 2017 includes an increase for NIH, but seeks some of it as mandatory funding.
Sure Genomics begins to offer direct-to-consumer genome sequencing for $2,500.
Intelligence officials in the US have added gene editing to a list of weapons of mass destruction.
This webinar will discuss the use of a hybrid capture-based FFPE DNA sequencing methodology with the potential for advancing precision oncology studies.